Use of ulipristal acetate, levonorgestrel and the copper-intrauterine device for emergency contraception following the introduction of new FSRH guidelines

Journal of Family Planning and Reproductive Health Care

Volumn 39, Issue 4, 2013, Pages 264-269

  Baird, Aisling Susan ^a  

^a Central Abacus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; ULIPRISTAL; CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE;

ADULT; ARTICLE; CONDOM USE; CONTROLLED STUDY; DECISION MAKING; EMERGENCY CONTRACEPTION; FEMALE; HEALTH SERVICE; HORMONAL CONTRACEPTION; HUMAN; LICENSING; MEDICAL INFORMATION SYSTEM; PRACTICE GUIDELINE; UNITED KINGDOM; CLINICAL PRACTICE; COPPER INTRAUTERINE DEVICE; DRUG UTILIZATION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TRENDS; UTILIZATION;

CONTRACEPTION, POSTCOITAL; CONTRACEPTIVE AGENTS; DRUG UTILIZATION; FEMALE; GREAT BRITAIN; HUMANS; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; NORPREGNADIENES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84884648903     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2012-100467     Document Type: Article

References (10)

1. Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: A systematic review of 35 years of experience. Hum Reprod 2012;27:1994-2000.
2. Gemzell-Danielsson K, Meng CX. Emergency contraception: potential role of ulipristal acetate. Int J Womens Health 2010;2:53-61.
3. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: A randomised controlled trial. Obstet Gynecol 2006;108:1089-1097.
4. Glasier AF, Cameron ST, Logan SJS, et al. Ulipristal acetate versus levonogestrel for emergency contraception: A randomised non-inferiority trial and meta-analysis. Lancet 2010;375:555-562.
5. Faculty of Sexual & Reproductive Healthcare Clinical Effectiveness Unit. Emergency Contraception. (August 2011, updated January 2012). http://www.fsrh.org/pdfs/CEUguidanceEmergencyContraception11.pdf [accessed 12 January 2013].
6. HRA Pharma UK Ltd. ellaOne: Summary of Product Characteristics (SPC). 2011. http://www.medicines.org.uk/emc[accessed 12 August 2012].
7. The National Statistics Socio-economic Classification. http://www.ons.gov.uk/ons/guide-method/classifications/current-standard- classifications/soc2010/soc2010-volume-3-ns-sec-rebased-on-soc2010-user-manual/ index.html#6 [accessed 12 January 2013].
8. The NHS Information Centre, Lifestyles Statistics. NHS Contraceptive Services: England, 2010/11 Community Contraceptives Clinics. 1 December 2011. https://catalogue.ic.nhs.uk/publications/public-health/contraception/ nhs-cont-serv-commcont-clin-eng-2010-2011/nhs-cont-serv-comm-cont-clin-eng-10- 11-rep.pdf [accessed 12 August 2012].
9. Thomas CM, Schmid R, Cameron S. Is it worth paying more for emergency hormonal contraception? The cost-effectiveness of ulipristal acetate versus levonorgestrel 1.5 mg. J Fam Plann Reprod Health Care 2010;36:197-201.
10. Stirling A, Glasier A. Estimating the efficacy of emergency contraception - how reliable are the data? Contraception 2001;66:19-22. Article.